Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vasopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 7/20 | 1.00 |
| ▸ | AVPR1B known ✓ | P47901 | 5/20 | 1.00 |
| ▸ | AVPR2 known ✓ | P30518 | 4/20 | 1.00 |
| ▸ | OXTR | P30559 | 4/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.88 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vasopressin SCHEMBL29688276 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL19712236 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL18937546 | 1.00 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL29530914 | 0.98 | AVPR1A (0.97) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL23879427 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL18476287 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL24390785 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL19733909 | 0.98 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL1172390 | 0.97 | AVPR1A (0.95) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL29500557 | 0.97 | AVPR1A (0.95) | AVPR1AAVPR1BAVPR2OXTRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 253 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3729101-B1 | WORKFLOW FOR RISK ASSESSMENT AND PATIENT MANAGEMENT USING PROCALCITONIN AND PROADRENOMEDULLIN | BRAHMS GMBH (DE) | 2026-03-18 | — | — | EP | claimed |
| EP-3781315-B1 | MICROFLUIDIC METHOD FOR SINGLE CELL ANALYSIS | HIFIBIO SAS (FR) | 2026-01-14 | — | — | EP | claimed |
| US-12466851-B2 | Manufacture of disulfide bonded peptides | BACHEM HOLDING AG (CH) | 2025-11-11 | — | — | US | claimed |
| WO-2025133225-A1 | PHARMACEUTICAL COMBINATION OF PEPTIDE-GLY AND PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) | PAM THERAGNOSTICS GMBH (DE) | 2025-06-26 | — | — | WO | claimed |
| US-20240316143-A1 | THERAPEUTIC AGENTS AND/OR PHARMACEUTICAL COMPOSITIONS FOR NEUROCOGNITIVE DISORDERS | IMAMURA Jyunichi (JP) | 2024-09-26 | — | — | US | claimed |
| EP-3655036-B1 | COMPOSITIONS FOR TREATING STRESS-RELATED DISORDERS | HOFFMAN TECH LLC (US) | 2024-09-04 | — | — | EP | claimed |
| WO-2024142211-A1 | THERAPEUTIC AGENT FOR DEMENTIA | 今村 純一 | 2024-07-04 | — | — | WO | claimed |
| US-11839540-B2 | Vena-caval apparatus and methods | MAGENTA MEDICAL LTD (IL) | 2023-12-12 | — | — | US | claimed |
| EP-3400000-B1 | METHODS FOR ADMINISTERING ANGIOTENSIN II | LA JOLLA PHARMA LLC (US) | 2023-12-06 | — | — | EP | claimed |
| EP-3631460-B1 | MMP-8 AS A MARKER FOR IDENTIFYING INFECTIOUS DISEASE | BRAHMS GMBH (DE) | 2023-11-15 | — | — | EP | claimed |
| EP-3803396-B1 | BIOMARKERS FOR THE DIAGNOSIS OF INVASIVE FUNGAL INFECTIONS | BRAHMS GMBH (DE) | 2023-03-01 | — | — | EP | claimed |
| US-20220213139-A1 | MANUFACTURE OF DISULFIDE BONDED PEPTIDES | BACHEM HOLDING AG (CH) | 2022-07-07 | — | — | US | claimed |
| US-20220151774-A1 | VENA-CAVAL APPARATUS AND METHODS | MAGENTA MEDICAL LTD. (IL) | 2022-05-19 | — | — | US | claimed |
| EP-3359129-B1 | ZINC COMPOSITIONS FOR COATED MICRONEEDLE ARRAYS | KINDEVA DRUG DELIVERY LP (US) | 2022-02-23 | — | — | EP | claimed |
| EP-4743176-A1 | DEUTERATED 1,3 DIHYDRO -2H-INDOLE-2-ONE DERIVATIVES | HMNC Holding GmbH (DE) | 2026-05-20 | — | — | EP | disclosed |
| US-12612442-B2 | G12-specific designer receptor exclusively activated by designer drugs | CELL NETWORKS GMBH (DE) | 2026-04-28 | — | — | US | disclosed |
| US-20260098068-A1 | GC-GLOBULIN FOR USE IN TREATING DIABETES | UNIV BIRMINGHAM (GB) | 2026-04-09 | — | — | US | disclosed |
| US-20170157202-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2017-06-08 | — | — | US | disclosed |
| US-20170035853-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT | 2017-02-09 | — | — | US | disclosed |
| US-9375478-B1 | Vasopressin formulations for use in treatment of hypotension | PAR PHARMACEUTICAL, INC. (US) | 2016-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098068-A1 | GC-GLOBULIN FOR USE IN TREATING DIABETES | GCGR, GCG, GCKR | AVPR1A 2469/4885AVPR1B 2718/4885AVPR2 2084/4885 |
| US-20170157202-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885AVPR1B 2/4885AVPR2 1/4885 |
| US-20240316143-A1 | THERAPEUTIC AGENTS AND/OR PHARMACEUTICAL COMPOSITIONS FOR NEUROCOGNITIVE DISORDERS | AVPR1A, AVPR2, AVPR1B | AVPR1A 1/4885AVPR1B 3/4885AVPR2 2/4885 |
| US-20170035853-A1 | VASOPRESSIN FORMULATIONS FOR USE IN TREATMENT OF HYPOTENSION | AVPR2, AVPR1B, AVPR1A | AVPR1A 3/4885AVPR1B 2/4885AVPR2 1/4885 |
| US-12612442-B2 | G12-specific designer receptor exclusively activated by designer drugs | RGS12, GNG2, GNAI1 | AVPR1A 273/4885AVPR1B 233/4885AVPR2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.